ArticleApplied biochemistry and biotechnology2026
USP17L2 Regulates SphK1 Ubiquitination and Stability during Autophagy and Pyroptosis in Mycoplasma Pneumoniae Pneumonia.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study explored the role of ubiquitin-specific peptidase 17-like family member 2 (USP17L2) and sphingosine kinase 1 (SphK1) in regulating macrophage autophagy and pyroptosis via the TRAF6-ULK1-NLRP3 signaling axis during Mp lipid exposure. Using in vitro and in vivo models, the study examines protein expression, cytokine levels, and cellular processes. Mechanistic explorations were performed on the mycoplasma pneumoniae pneumonia (MPP) models. Mp lipid treatment significantly upregulated SphK1 and USP17L2 expression in MH-S cells while promoting proinflammatory cytokine secretion, ROS production, and activation of pyroptosis and autophagy. Silencing SphK1 suppressed Mp lipid-induced macrophage autophagy, pyroptosis, and activation of the TRAF6-ULK1 signaling axis. Co-IP confirmed direct interaction between SphK1 and TRAF6, with SphK1 inducing ULK1 ubiquitination. USP17L2 was a specific deubiquitinating enzyme for SphK1, and the two proteins interacted. Silencing USP17L2 significantly reduced inflammatory infiltration in lung tissue, neutrophil recruitment in bronchoalveolar lavage fluid, and bacterial load in MPP mice. Concurrently, it suppressed the expression of autophagy-related molecules, pyroptosis-related molecules, and proinflammatory factors in lung tissue. In conclusion, USP17L2 stabilizes SphK1 through deubiquitination modification and activates the TRAF6-ULK1-NLRP3 signaling axis, thereby promoting macrophage autophagy and pyroptosis and exacerbating MPP damage. Silencing USP17L2 blocks this regulatory pathway, inhibiting excessive inflammatory responses and cell death.
Indexed as
Identifiers
41762357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.